Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs

被引:29
作者
Nakata, Hirotorno [1 ,2 ,3 ]
Steinberg, Seth M. [4 ]
Koh, Yasuhiro [1 ,2 ]
Maeda, Kenji [3 ]
Takaoka, Yoshikazu [5 ]
Tarnarnura, Hirokazu [6 ]
Fujii, Nobutaka [6 ]
Mitsuya, Hiroaki [1 ,2 ,3 ]
机构
[1] Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Dept Infect Dis, Kumamoto 8608556, Japan
[2] Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Dept Hematol, Kumamoto 8608556, Japan
[3] NCI, Ctr Canc Res, Expt Retrovirol Sect, HIV & AIDS Malignancy Branch,NIH, Bethesda, MD 20892 USA
[4] NCI, Biostat & Data Management Sect, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[5] Ono Pharmaceut Co Ltd, Osaka 6188585, Japan
[6] Kyoto Univ, Sakyo Ku, Grad Sch Pharmaceut Sci, Kyoto 6068501, Japan
关键词
D O I
10.1128/AAC.01299-07
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Aplaviroc (AVC), an experimental CCR5 inhibitor, potently blocks in vitro the infection of R5-tropic human immunodeficiency virus type 1 (R5-HIV-1) at subnanomolar 50% inhibitory concentrations. Although maraviroc is presently clinically available, further studies are required to determine the role of CCR5 inhibitors in combinations with other drugs. Here we determined anti-HIV-1 activity using combinations of AVC with various anti-HIV-1 agents, including four U.S. Food and Drug Administration-approved drugs, two CCR5 inhibitors (TAK779 and SCH-C) and two CXCR4 inhibitors (AMD3100 and TE14011). Combination effects were defined as synergistic or antagonistic when the activity of drug A combined with B was statistically greater or less, respectively, than the additive effects of drugs A and A combined and drugs B and B combined by using the Combo method, described in this paper, which provides (i) a flexible choice of interaction models and (ii) the use of nonparametric statistical methods. Synergistic effects against R5-HIV-1(Ba-L), and a 50:50 mixture of R5-HIV-1(Ba-L) and X4-HIV-1(ERS104pre) (HIV-1(Ba-L/104pre)) were seen when AVC was combined with zidovudine, nevirapine, indinavir, or enfuvirtide. Mild synergism and additivity were observed when AVC was combined with TAK779 and SCH-C, respectively. We also observed more potent synergism against HIV-1(Ba-L/104pre) when AVC was combined with AMD3100 or TE14011. The data demonstrate a tendency toward greater synergism with AVC plus either of the two CXCR4 inhibitors compared to the synergism obtained with combinations of AVC and other drugs, suggesting that the development of effective CXCR4 inhibitors may be important for increasing the efficacies of CCR5 inhibitors.
引用
收藏
页码:2111 / 2119
页数:9
相关论文
共 42 条
[1]   CC CKRS: A RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1 [J].
Alkhatib, G ;
Combadiere, C ;
Broder, CC ;
Feng, Y ;
Kennedy, PE ;
Murphy, PM ;
Berger, EA .
SCIENCE, 1996, 272 (5270) :1955-1958
[2]   A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity [J].
Baba, M ;
Nishimura, O ;
Kanzaki, N ;
Okamoto, M ;
Sawada, H ;
Iizawa, Y ;
Shiraishi, M ;
Aramaki, Y ;
Okonogi, K ;
Ogawa, Y ;
Meguro, K ;
Fujino, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (10) :5698-5703
[3]   GENERALIZED EQUATIONS FOR THE ANALYSIS OF INHIBITIONS OF MICHAELIS-MENTEN AND HIGHER-ORDER KINETIC SYSTEMS WITH 2 OR MORE MUTUALLY EXCLUSIVE AND NON-EXCLUSIVE INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1981, 115 (01) :207-216
[4]   QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55
[5]   Baseline HIV type 1 coreceptor tropism predicts disease progression [J].
Daar, Eric S. ;
Kesler, L. ;
Petropoulos, J. ;
Huang, Wei ;
Bates, Michael ;
Lail, Alice E. ;
Coakley, Eoin P. ;
Gomperts, Edward D. ;
Donfield, Sharyne M. .
CLINICAL INFECTIOUS DISEASES, 2007, 45 (05) :643-649
[6]   Strategies in the design of antiviral drugs [J].
De Clercq, E .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (01) :13-25
[7]   HIGHLY POTENT AND SELECTIVE-INHIBITION OF HUMAN-IMMUNODEFICIENCY-VIRUS BY THE BICYCLAM DERIVATIVE JM3100 [J].
DE CLERCQ, E ;
YAMAMOTO, N ;
PAUWELS, R ;
BALZARINI, J ;
WITVROUW, M ;
DEVREESE, K ;
DEBYSER, Z ;
ROSENWIRTH, B ;
PEICHL, P ;
DATEMA, R ;
THORNTON, D ;
SKERLJ, R ;
GAUL, F ;
PADMANABHAN, S ;
BRIDGER, G ;
HENSON, G ;
ABRAMS, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (04) :668-674
[8]  
DEMAREST J, 2004, 44 INT C ANT AG CHEM
[9]   Identification of a major co-receptor for primary isolates of HIV-1 [J].
Deng, HK ;
Liu, R ;
Ellmeier, W ;
Choe, S ;
Unutmaz, D ;
Burkhart, M ;
DiMarzio, P ;
Marmon, S ;
Sutton, RE ;
Hill, CM ;
Davis, CB ;
Peiper, SC ;
Schall, TJ ;
Littman, DR ;
Landau, NR .
NATURE, 1996, 381 (6584) :661-666
[10]   Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity [J].
Dorr, P ;
Westby, M ;
Dobbs, S ;
Griffin, P ;
Irvine, B ;
Macartney, M ;
Mori, J ;
Rickett, G ;
Smith-Burchnell, C ;
Napier, C ;
Webster, R ;
Armour, D ;
Price, D ;
Stammen, B ;
Wood, A ;
Perros, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (11) :4721-4732